AMGEN AND GENERATE BIOMEDICINES ANNOUNCE MULTI-TARGET, MULTI-MODALITY RESEARCH COLLABORATION AGREEMENT

THOUSAND OAKS, Calif. and CAMBRIDGE, Mass.: THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., Jan. 6, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Generate Biomedicines today announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities. As part of the...

Click to view original post